Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the UK, starting from September, amid pressure from the Trump administration to bring prices down in the US. The company confirmed that a month’s supply of the highest dose will rise from £122 ($165) to £330 ($447), representing a 170% increase.
However, prices for Mounjaro accessed through the NHS, the UK’s public health service, will remain unchanged. Around 220,000 Brits are expected to access the drug through the NHS in its first three years of introduction.
Eli Lilly cited new clinical evidence supporting the value of Mounjaro as a reason for the price increase. The company had initially agreed a lower list price in the UK to prevent delays in NHS availability when the drug was first launched.
The move comes amid intense pressure from President Trump, who has accused foreign nations of “freeloading” at the expense of American innovation. Eli Lilly stated that it aims to keep the US as the global leader in drug research and manufacturing.
The company’s decision reflects the ongoing efforts to align prices across developed countries, especially in Europe. While some experts question Trump’s ability to force price changes directly, his executive order may encourage pharmaceutical companies to change their pricing voluntarily.
In related news, a private weight-loss clinic in the UK has published a blog offering Mounjaro patients a pathway to switch to a competing weight-loss jab manufactured by Novo Nordisk.
Source: https://edition.cnn.com/2025/08/15/business/eli-lilly-mounjaro-price-rises-uk